Investor Presentation First Nine Months of 2022
Novo NordiskⓇ
109
Investor presentation First nine months of 2022
IO remains committed to its strategic aspiration of 6-10% growth
driven by securing the base and three future growth enablers
Growing double digits every year since 2019
Driving market growth via a market-fit approach
ILLUSTRATIVE
5%
6-10%
Driving GLP-1
growth
OZEMPIC RYBELSUS
semaglutide injection
semaglutide tablets
Ⓡ
ONCE-WEEKLY
Expand Obesity Saxenda Wegovy
care
liraglutide injection
semaglutide injection 2.4 mg
Expand insulin
TRESIBA
insulin degludec [rDNA origin] injection
RYZODEG®
70% insulin degludec and 30% insulin aspart
[rDNA origin] injection
Prepare for Icodec
sales and
patient base
2013
2018
2025
Future growth drivers
Base sales with mature therapy areas
Note: All growth rates in Constant Exchange Rates (CER) unless otherwise specified.View entire presentation